Autopsy report · NCT00492843

Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis

“It is too difficult to recruit suitable patients.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year before it stopped.
• 20 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Chinese Society of Lung Cancer

Sponsor type

University, hospital or other

Conditions

Lung Cancer

Interventions

Ibandronate (Bondronat)

Participants

20

Sites

8

Countries

China

Trials that died the same way

• Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy
  “difficult to recruit patients” (87% match in meaning)
• Effects of Intraarticular IL1-Ra on Pain and Inflammatory Mediators After Knee Arhroscopy
  “Too few recruitable patients” (85% match in meaning)
• Effects of Fish or Meat Consumption in Elderly
  “Not enough patients to recruite.” (84% match in meaning)
• Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intrathecal Injection for ALS
  “Inability to recruit patients” (83% match in meaning)
• Neuropsychological Effects of Hydrocortisone in Patients With Partial Adrenal Insufficiency
  “Insufficient recruitment of suitable patients.” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.